Ocular Regenerative Medicine

Canadian Ocular Regenerative Medicine Society

AllSunday June 18, 1045—1215
Room 522ABC

Learning objectives

At the end of this session, participants will be able to:

  • Explain how limbal stem cells are expanded ex vivo and transplanted
  • Assess the efficacy of cell injection and regenerative therapy in endothelial disease
  • Assess the efficacy and state of the art of biosynthesis substitutes in treating corneal disease

GUEST SPEAKERS

Jodhbir S. Mehta, Bsc (Hons.), MBBS, FRCOphth, FRCS (Ed.), FAMS
Graziella Pellegrini, MD

MODERATORS

Isabelle Brunette, MD
Allan Slomovic, MSc, MD

FACULTY

Brian Ballios, MD
May Griffith, MD
Jacky Slomovic, BSc


Agenda

1045 Regenerative medicine of the ocular surface: What is missing • Graziella Pellegrini
1100 Assessing the efficacy of cell injection and tissue engineered endothelial keratoplasty for endothelial disease • Jodhbir S. Mehta
1110 The first stem cell treatment EU approved • Graziella Pellegrini
1120 Regenerative therapy in Fuchs’ corneal dystrophy: • Jodhbir S. Mehta
1130 National ocular stem cell registry • Brian Ballios, Isabelle Brunette, Jacky Slomovic, Allan Slomovic
1145 Biosynthetic corneal substitutes: Has it become a reality? • May Griffith
1200 Canadian Ocular Regenerative Medicine Society business meeting
1215 Adjourn